Other functional studies reinforced these differences between MAGE expressions in thyroid lesions, suggesting that MAGE A3/6 and FGFR2-IIIb participate in the development of thyroid cancer [22]. This evidence concerns the gene FGFR2 and thyroid gland carcinoma.